1. Symptom lead times in lung and colorectal cancers: what are the benefits of symptom-based approaches to early diagnosis?
- Author
-
Mousumi Biswas, William Hamilton, and A E Ades
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Colorectal cancer ,Primary health care ,colorectal cancer ,Sensitivity and Specificity ,Internal medicine ,medicine ,Humans ,Lung cancer ,Lead (electronics) ,Early Detection of Cancer ,Lung ,Primary Health Care ,business.industry ,Incidence ,Incidence (epidemiology) ,Case-control study ,respiratory system ,medicine.disease ,Surgery ,lung cancer ,medicine.anatomical_structure ,Case-Control Studies ,Symptom-based diagnosis ,Clinical Study ,Colorectal Neoplasms ,business ,Symptom lead time - Abstract
Background: Individuals with undiagnosed lung and colorectal cancers present with non-specific symptoms in primary care more often than matched controls. Increased access to diagnostic services for patients with symptoms generates more early-stage diagnoses, but the mechanisms for this are only partially understood.Methods: We re-analysed a UK-based case–control study to estimate the Symptom Lead Time (SLT) distribution for a range of potential symptom criteria for investigation. Symptom Lead Time is the time between symptoms caused by cancer and eventual diagnosis, and is analogous to Lead Time in a screening programme. We also estimated the proportion of symptoms in lung and colorectal cancer cases that are actually caused by the cancer.Results: Mean Symptom Lead Times were between 4.1 and 6.0 months, with medians between 2.0 and 3.2 months. Symptom Lead Time did not depend on stage at diagnosis, nor which criteria for investigation are adopted. Depending on the criteria, an estimated 27–48% of symptoms in individuals with as yet undiagnosed lung cancer, and 12–32% with undiagnosed colorectal cancer are not caused by the cancer.Conclusions: In most cancer cases detected by a symptom-based programme, the symptoms are caused by cancer. These cases have a short lead time and benefit relatively little. However, in a significant minority of cases cancer detection is serendipitous. This group experiences the benefits of a standard screening programme, a substantial mean lead time and a higher probability of early-stage diagnosis
- Published
- 2014